Akèy › Kansè Poumon ki pa ti selil › Florid › St. Petersburg
Etid klinik pou Kansè Poumon ki pa ti selil nan St. Petersburg, FL
21 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote St. Petersburg (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Saint Anthony's Hospital Cancer Care Center, St. Petersburg
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- Florida Cancer Specialists - NORTH - SCRI - PPDS, St. Petersburg
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Florida Cancer Specialists - NORTH - SCRI - PPDS, St. Petersburg
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Moffitt Cancer Center at SouthShore, Ruskin · 15 mi lwen
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Comprehensive Hematology Oncology /ID# 270422, St. Petersburg
- Florida Cancer Specialists - North /ID# 271995, St. Petersburg
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Ap rekriteFaz 3
- Comprehensive Hematology Oncology, St. Petersburg
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Florida Cancer Specialists & Research Institute - North, St. Petersburg
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Florida Cancer Specialists, St. Petersburg
- Florida Cancer Specialists, St. Petersburg
- Florida Cancer Specialists, Bradenton · 20 mi lwen
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, St. Petersburg
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Florida Cancer Specialists & Research Institute 1, St. Petersburg
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Comprehensive Hematology Oncology (CHO), St. Petersburg
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Florida Cancer Specialists North, St. Petersburg
- Comprehensive Hematology Oncology, St. Petersburg
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Florida Cancer Specialists - North, St. Petersburg
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- Local Institution - 0695, St. Petersburg
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, St. Petersburg
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-922-D, Bradenton · 20 mi lwen
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Comprehensive Hematology Oncology, St. Petersburg
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Comprehensive Hematology Oncology, St. Petersburg
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, St. Petersburg
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Florida Cancer Specialists North, St. Petersburg
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Saint Anthony's Hospital Cancer Care Center, St. Petersburg
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan St. Petersburg
- Kansè nan tete11 etid
- Sipwa8 etid
- Obèsite8 etid
- Ensifizyans kadyak8 etid
- Kansè kolorektal8 etid
- Kansè poumon7 etid
- Kansè Endomèt6 etid
- Limfòm Burkitt6 etid
- Kansè ovè6 etid
- Dyabèt Tip 25 etid
- Dematit atopik (Ekzema)5 etid
- BPCO5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 7, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.